# | Title | Journal | Year | Citations |
---|
1 | Basic principles of ROC analysis | Seminars in Nuclear Medicine | 1978 | 5,105 |
2 | 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation | Seminars in Nuclear Medicine | 2002 | 495 |
3 | X-ray-based attenuation correction for positron emission tomography/computed tomography scanners | Seminars in Nuclear Medicine | 2003 | 448 |
4 | Imaging of Neuroendocrine Tumors | Seminars in Nuclear Medicine | 2006 | 387 |
5 | Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience | Seminars in Nuclear Medicine | 2002 | 364 |
6 | Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation | Seminars in Nuclear Medicine | 1996 | 358 |
7 | Positron emission tomography for prostate, bladder, and renal cancer | Seminars in Nuclear Medicine | 2004 | 312 |
8 | Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings | Seminars in Nuclear Medicine | 2002 | 307 |
9 | PET imaging in oncology | Seminars in Nuclear Medicine | 2000 | 306 |
10 | Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors | Seminars in Nuclear Medicine | 2006 | 283 |
11 | Respiratory Motion in Positron Emission Tomography/Computed Tomography: A Review | Seminars in Nuclear Medicine | 2008 | 281 |
12 | Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole | Seminars in Nuclear Medicine | 2007 | 274 |
13 | Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate | Seminars in Nuclear Medicine | 2001 | 254 |
14 | Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies | Seminars in Nuclear Medicine | 2002 | 247 |
15 | 18F-fluoride for bone imaging | Seminars in Nuclear Medicine | 1972 | 246 |
16 | Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging | Seminars in Nuclear Medicine | 2004 | 241 |
17 | Positron Emission Tomography as a Diagnostic Tool in Infection: Present Role and Future Possibilities | Seminars in Nuclear Medicine | 2009 | 231 |
18 | Radionuclide imaging in orthopedic infections | Seminars in Nuclear Medicine | 1997 | 225 |
19 | 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial | Seminars in Nuclear Medicine | 2002 | 225 |
20 | PET/CT scanners: A hardware approach to image fusion | Seminars in Nuclear Medicine | 2003 | 224 |
21 | Nuclear Medicine and the Infected Joint Replacement | Seminars in Nuclear Medicine | 2009 | 224 |
22 | Positron emission tomography and bone metastases | Seminars in Nuclear Medicine | 2005 | 218 |
23 | Therapeutic Radionuclides: Biophysical and Radiobiologic Principles | Seminars in Nuclear Medicine | 2008 | 216 |
24 | Evolution of Tc-99m in diagnostic radiopharmaceuticals | Seminars in Nuclear Medicine | 2001 | 212 |
25 | Somatostatin receptor imaging | Seminars in Nuclear Medicine | 2002 | 212 |
26 | Technical principles of dual energy X-ray absorptiometry | Seminars in Nuclear Medicine | 1997 | 209 |
27 | Radionuclide Imaging of the Parathyroid Glands | Seminars in Nuclear Medicine | 2005 | 206 |
28 | Positron Emission Tomography/Magnetic Resonance Imaging: The Next Generation of Multimodality Imaging? | Seminars in Nuclear Medicine | 2008 | 206 |
29 | Positron emission tomography imaging in nonmalignant thoracic disorders | Seminars in Nuclear Medicine | 2002 | 203 |
30 | Functional Imaging of Inflammatory Diseases Using Nuclear Medicine Techniques | Seminars in Nuclear Medicine | 2009 | 199 |
31 | Multimodality Imaging: Beyond PET/CT and SPECT/CT | Seminars in Nuclear Medicine | 2009 | 199 |
32 | The treatment of thyroid carcinoma with radioactive iodine | Seminars in Nuclear Medicine | 1978 | 198 |
33 | Evolving role of positron emission tomography in breast cancer imaging | Seminars in Nuclear Medicine | 2005 | 195 |
34 | Paramagnetic contrast agents in nuclear magnetic resonance medical imaging | Seminars in Nuclear Medicine | 1983 | 194 |
35 | The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast | Seminars in Nuclear Medicine | 2006 | 192 |
36 | 18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor Localization | Seminars in Nuclear Medicine | 2007 | 192 |
37 | Benign causes of 18-FDG uptake on whole body imaging | Seminars in Nuclear Medicine | 1998 | 188 |
38 | Increased 18F-Fluorodeoxyglucose Uptake in Benign, Nonphysiologic Lesions Found on Whole-Body Positron Emission Tomography/Computed Tomography (PET/CT): Accumulated Data From Four Years of Experience With PET/CT | Seminars in Nuclear Medicine | 2007 | 188 |
39 | PET and SPECT in Osteomyelitis and Prosthetic Bone and Joint Infections: A Systematic Review | Seminars in Nuclear Medicine | 2010 | 185 |
40 | PET in oncology: Will it replace the other modalities? | Seminars in Nuclear Medicine | 1997 | 183 |
41 | 68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives | Seminars in Nuclear Medicine | 2011 | 183 |
42 | Antibody Vectors for Imaging | Seminars in Nuclear Medicine | 2010 | 182 |
43 | SPECT/CT in tumor imaging: Technical aspects and clinical applications | Seminars in Nuclear Medicine | 2003 | 179 |
44 | Whole-body FDG-PET imaging in the management of patients with cancer | Seminars in Nuclear Medicine | 2002 | 178 |
45 | Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers | Seminars in Nuclear Medicine | 1997 | 177 |
46 | The current role of gallium imaging in infection | Seminars in Nuclear Medicine | 1994 | 176 |
47 | 18F FDG uptake in the large arteries: A correlation study with the atherogenic risk factors | Seminars in Nuclear Medicine | 2002 | 176 |
48 | Radioimmunoassay of plasma renin activity | Seminars in Nuclear Medicine | 1975 | 174 |
49 | Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International consensus committee from the scientific committee of radionuclides in nephrourology | Seminars in Nuclear Medicine | 1999 | 174 |
50 | 18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed Tomography | Seminars in Nuclear Medicine | 2007 | 174 |